The primary objective of this trial is to evaluate the Safety, Efficacy, and Standardized Procedural Optimization of the Intracranial Drug-Eluting Stent System in Patients with Symptomatic Intracranial Atherosclerotic Stenosis.
Males or females between 18 and 80 years of age
Symptomatic intracranial arteriosclerosis stenosis with reference diameter 2.25-4.00mm
Intracranial artery stenosis ( ≥70%) conformed by DSA
Those who voluntarily participate in the study and sign informed consent form
Those who have surgery within previous 30 days or plan to perform major surgery in the next 90 days (surgery grade 3 and above);
Subjects of acute hemorrhagic stroke within 3 months;
The baseline mRS of disabling stroke is more than 3;
The target vessel is severely calcified and closely related to stenosis;
Sino Medical Sciences Technology Inc.
Lead sponsor
The First Affiliated Hospital of Zhengzhou University
Collaborator
Tongji Hospital
Collaborator